New research reveals teclistamab and daratumumab significantly enhance progression-free survival in multiple myeloma, reshaping treatment standards. Maria-Victoria Mateos, MD, PhD, closed out the late ...
Histopathological image of multiple myoloma. Smear preparation of bone marrow aspirate stained with May-Grünwald-Giemsa procedure. It doest not represent a histopathologic image but essentially helps ...
Immunotherapy is a type of cancer treatment that uses the power of a person’s immune system to fight their cancer. Instead of directly attacking cancer cells like chemotherapy or radiation, ...
Hosted on MSN
Combination treatment shows large improvement in survival for people with relapsed myeloma
At the American Society of Hematology Conference in Orlando, new results from the MajesTEC-3 study show that combining teclistamab with daratumumab could help people with myeloma whose cancer has come ...
Multiple myeloma diagnosis integrates blood tests, genetic assessments, and imaging to guide personalized treatment and patient engagement. Smoldering multiple myeloma involves active surveillance to ...
Significant unmet need for patients requires new and novel treatments1 DREAMM-7 showed a 51% reduction in the risk of death and tripled median progression-free survival in 3L+ indicated population ...
The study involved 587 patients whose cancer had returned after previous treatments. Some patients received the standard of care treatment, and others received the new combination treatment of ...
Stage 3 multiple myeloma is defined by high beta-2 microglobulin, elevated LDH, and high-risk genetic abnormalities. Diagnosis involves CRAB criteria and tests like bone marrow biopsy, imaging, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results